An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa--authors' response

Burcu Isler^{1

2}, Patrick Harris^{1

3}, Adam G Stewart^{1

2}, David L Paterson^{1

2}

Affiliations

¹ University of Queensland, Faculty of Medicine, UQ Centre for Clinical Research, Brisbane, Australia.
² Infectious Diseases Unit, Royal Brisbane and Women's Hospital, Brisbane, Australia.
³ Central Microbiology, Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, Australia.

Comment

Burcu Isler et al. J Antimicrob Chemother. 2021.

. 2021 Nov 12;76(12):3327-3328.

doi: 10.1093/jac/dkab366.

Burcu Isler^{1

2}, Patrick Harris^{1

3}, Adam G Stewart^{1

2}, David L Paterson^{1

2}

¹ University of Queensland, Faculty of Medicine, UQ Centre for Clinical Research, Brisbane, Australia.
² Infectious Diseases Unit, Royal Brisbane and Women's Hospital, Brisbane, Australia.
³ Central Microbiology, Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, Australia.

No abstract available

Comment on

An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa.
Isler B, Harris P, Stewart AG, Paterson DL. Isler B, et al. J Antimicrob Chemother. 2021 Feb 11;76(3):550-560. doi: 10.1093/jac/dkaa511. J Antimicrob Chemother. 2021. PMID: 33332545
Comment on: An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa.
Nicolau DP, Bhagwat SS, Abdelraouf K. Nicolau DP, et al. J Antimicrob Chemother. 2021 Nov 12;76(12):3326-3327. doi: 10.1093/jac/dkab229. J Antimicrob Chemother. 2021. PMID: 34179957 No abstract available.